Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.

Abstract: The present invention relates to a microfluidic device to manipulate, select, treat, or cultivate living bodies, comprising a first chamber, a second chamber and a network of guiding tracks, wherein: said network of guiding tracks comprises at least one first guiding track connecting the first chamber and the second chamber and at least one second guiding track connecting said at least one first guiding track with at least two interconnections; and said at least one second guiding track comprises a curved part; said curved part exhibiting a concavity facing the second chamber or the part of the network connected to the second chamber.

Abstract: Methods for detecting and/or measuring the level of sodium-dependent multivitamin transporter (SMVT) in a biological sample. The methods include the steps of: (a) contacting the biological sample with a PERV-B.RBD ligand, a variant and/or a fragment thereof; and, detecting and/or measuring the binding of the PERV-B.RBD ligand, variant and/or fragment thereof to SMVT.

Abstract: The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.

Abstract: The present invention relates to a method for ex vivo generating and expanding ?? Foxp3+ regulatory T cells, and therapeutic uses thereof. The inventors performed the induction of Foxp3+ expression in ex vivo human induced tumor-antigen specific CD4+ TCR?? unrestricted T cells and the induction of autologous CD8-mediated T-cell responses against tumor-antigen specific FOXP3 expressing CD4+ TCR?? unrestricted T cells. The inventors developed a method to ex vivo generated and expanded antigen specific Foxp3 expressing CD3+ TCR??+ unrestricted T cells, committed to exclusively exert regulatory activity, whichever culture condition of stimulation is. In particular, the present invention relates to a method for generating ex vivo ?? Foxp3+ regulatory T cells having the following phenotype: CD3+ TCR??+ Foxp3+.

Abstract: This oscillator comprises: a source generating an incident optical wave at a pulsation frequency ?; an optomechanical resonator, having optical resonances at the pulsation frequency ? and mechanical resonances at a frequency f1 and generating, from the incident optical wave, emergent optical waves at the pulsation frequencies ? and ??2?f1, and an acoustic wave at frequency f1; and, a photodiode delivering a useful signal at frequency f1 from the emergent waves. This oscillator further comprises: an acoustic propagation means for propagating the acoustic wave over a distance in order to produce a delayed acoustic wave; a means for converting the delayed acoustic wave into a delay signal at the frequency f1; and, a control loop, processing the delay signal in order to obtain a control signal applied to the source.

Abstract: A regenerative material in the connective tissues (such as bone, dentin or pulp) regeneration field. More precisely, a connective tissue regenerative material, preferably a bone, dentin or pulp regenerative material, including: a porous polymer matrix having interconnected pores; and non-hydrated calcium silicate particles; wherein: the polymer matrix is anhydrous; the non-hydrated calcium silicate particles have a d50granulometry, preferably ranging from 0.05 ?m to less than the average diameter size of the pores of the matrix; and the non-hydrated calcium silicate particles being coated on the inside walls of the pores of the matrix. Also, a method for preparing the connective tissue regenerative material and uses of the regenerative materials, such as in the dental field; especially, for providing regenerative materials with improved biomechanical and osteoinductive properties (i.e.

Abstract: The present invention relates to a composition comprising secreted extracellular vesicles (SEV) of cells expressing nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4(NFATC4), for use in the treatment of cancer or in the treatment or prevention of metastatic cancer. It further relates to in vitromethods for determining or predicting the therapeutic efficiency of a treatment with a composition comprising SEV of cells expressing NFATC4 in a cancer patient, based on the ability of the composition comprising SEV of cells expressing NFATC4 to induce an increase in TGF?1 expression level.

Abstract: The present invention generally relates to an immunogenic construct, useful for redirecting an EBV-existing immune response towards an undesired target cell and/or microorganism, to methods for preparing said conjugate, to a pharmaceutical applications comprising said conjugate, and to medical applications thereof.

Abstract: This invention relates to the direct grafting of a calixarene mostly onto the surface of a material, as well as to a grafting process, and certain calixarene intermediates useful for carrying the grafting process.

Abstract: A microfluidic device for processing particles, including: an elongated chamber including elongated segment(s), input seeding channel(s) and one output seeding channel defining a seeding flow transverse to the longitudinal direction of the segment, input harvest channel(s) and one output harvest channel defining a harvest flow in the longitudinal direction, wherein, for the segment, a single input seeding tree defines input seeding channels and a single output seeding tree defines output seeding channels, junctions of the input seeding channels and output seeding channels with the processing chamber being distributed along the segment on both sides of the chamber, wherein: Rs_input ? S 2 ? 1 ( ? k ? V k * S k ) / V TOTs ? _ ? inpu ? t is higher than 50, S21 being the segment cross section perpendicular to the transverse direction, (?k Vk*Sk)/VTOTs_input being, the sum of the products of the volume and the cross section of the input seeding channel, divided by the total volume V

Abstract: The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to the inflammation induced by P. acnes, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.

Abstract: A device for automatically imaging the capillary blood vessels of a living tissue likely to move, configured for selecting images of the sequence, called ‘sharp images’, arranged in chronological order of acquisition, shuffling the sharp images, for decorrelating temporally the sharp images, by arranging them in a shuffled order different from the chronological order, realigning spatially the sharp images arranged in the shuffled order, generating a projected image by projection of the pixels of the realigned sharp images, in a stack, the projected values of the pixels forming the projected image being extremal intensity values of the pixels of all the sharp images, the projection of the extremal of intensity values of the pixels rendering all the positions of all erythrocytes of all the sharp images in the projected image.

Abstract: Method and photo-electrochemical system using Cu(In,Ga)Se2 CIGS for reducing electrochemically CO2 into CO using as catalyst a metal complex with quaterpyridine ligand, the electrochemical cell comprising a cathode, an anode, a cathodic electrolyte comprising water as the solvent, and a power supply providing the energy necessary to trigger the electrochemical reactions.

Abstract: Disclosed is CD31shed for use as a molecular imaging target in the molecular imaging of an inflammatory condition. Administering the radiolabeled peptide P8RI as CD31shed ligand in different rat models of inflammation indeed showed that CD31shed is present on activated cells in a quantity allowing a detectable signal, whereas the noise signal corresponding to CD31shed present on activated circulating cells and on other organs or cells not involved in inflammation was little. Also disclosed is a labeled CD31shed ligand and the use thereof as a molecular imaging agent in the molecular imaging of an inflammatory condition. The molecular imaging of inflammatory sites particularly allows determining whether a subject suffers from or is at risk of having an inflammatory condition or is at risk of recurrence of an inflammatory condition after an anti-inflammatory treatment.

Abstract: The present invention relates to methods for predicting acute severe colitis treatment response. Currently, there is no biomarker of drug response. The present invention provides the first prediction tool for responses to first- and second-line treatments in acute severe ulcerative colitis. Putative mRNA targets of dysregulated microRNAs were identified from patient biopsies. One classifier of fifteen colonic microRNAs plus five biological values at admission were identified with a prediction accuracy of 96.6% for discriminating responders from non-responders to steroids. Using a similar method, 6 and 4 mucosal microRNA-based algorithms were identified to classify responders from non-responders to infliximab and cyclosporine.

Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydrocarbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.

Abstract: The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydro-carbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.

Abstract: The present invention relates to novel bis-hydrazone derivatives of formula (I): wherein Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of groups of formula (II) and (III): Y1 and Z1 are independently CH or NRc+, provided that al least one of Y1 and Z1 is NRc+ and at least one of Y1 and Z1 is CH, and Ra, Rb, Rc, X2? and L as defined in the claims, or a hydrate or a solvate thereof. Compositions and kits comprising same are also described. Said bis-hydrazone derivatives of formula (I), compositions and kits are useful as drugs, in particular for treating or preventing cancers associated with the Epstein-Barr Virus.

Abstract: A real-time diagnosis aid method including: (a) providing a decision-support system for autonomous medical diagnosis to a user of a medical system, the system comprising a display module and software modules embodied on a computer readable medium; (b) generating on the display module an ordered list of diagnostic clues to look at by the user according to the diagnostic clues already filled in as absent or present, the ordered list being based on the relevance of looking at respective diagnostic clues to quickly lead to a diagnosis by the user; (c) receiving from the user, information on presence or absence of one or more diagnosis clues listed in the ordered list; and (d) processing the received information to update the ordered list and provide on the display module an indication of the probability of each possible diagnosis.